IDEAYA Biosciences, Inc. filings document the regulatory record of a Nasdaq-listed precision oncology company developing targeted therapeutics and biomarker-directed cancer programs. Recent 8-K reports cover financial results, business updates, clinical data from the OptimUM darovasertib program, collaboration agreements involving investigational oncology assets, and Regulation FD corporate presentations.
The company’s SEC record also includes proxy materials for annual meeting governance, executive compensation and equity-plan matters. Registration and prospectus filings describe IDEAYA’s common stock, automatic shelf registration capacity, at-the-market sales arrangements and related capital-structure disclosures, alongside risk and pipeline information tied to its clinical-stage oncology portfolio.
At IDEAYA Biosciences, Inc. (IDYA), President and CEO and director Yujiro S. Hata exercised 26,338 stock options on October 6, 2026, at $4.31 per share. He then sold 25,538 common shares at a weighted average sale price of $37.3869 per share and 800 shares at a weighted average sale price of $38.2626 per share; both sales were under a Rule 10b5-1 trading plan adopted July 7, 2026. His reported remaining option position was 23,116 options, expiring February 26, 2028.
IDEAYA Biosciences, Inc. CEO Yujiro Hata reported a proposed sale of 230,316 common shares, with an aggregate market value of $8,804,981 and an approximate sale date of October 6, 2026. J.P. Morgan Securities LLC is listed as broker, and Nasdaq as the exchange. The stated sales will include cashless option exercises occurring within three months of the filing date.
IDEAYA Biosciences, Inc. has a significant institutional holder group led by Baker Bros. Advisors LP and related entities and individuals. These reporting persons disclose beneficial ownership of 5,010,030 shares of IDEAYA common stock, representing 5.2% of the class based on 96,375,637 shares outstanding as of June 30, 2026.
The shares are held through Baker Brothers Life Sciences, L.P. and 667, L.P., with Baker Bros. Advisors LP having sole voting and dispositive power under management agreements. The funds also hold prefunded warrants with a $0.0001 per-share exercise price and no expiration date. These warrants are only exercisable to the extent that, after exercise, the holders and certain affiliates would not beneficially own more than a specified Maximum Percentage, initially 4.99%, adjustable by written notice up to 19.99% effective after 61 days. Due to these limitations, the funds cannot presently exercise any of the prefunded warrants.
IDEAYA Biosciences reported collaboration revenue of $8.9 million for the quarter and $15.4 million for the six months ended June 30, 2026, entirely from its Servier darovasertib license. Operating expenses rose sharply, with research and development at $108.7 million and general and administrative at $22.5 million for the quarter.
This drove a quarterly net loss of $112.5 million and a six‑month net loss of $211.0 million. Liquidity strengthened through a June 2026 follow‑on offering of 7,222,225 shares and 5,555,576 pre‑funded warrants, generating $345.0 million in gross and $323.4 million in net proceeds, plus at‑the‑market sales of 1,196,423 shares for $33.1 million in net proceeds. Cash, cash equivalents and marketable securities totaled approximately $1.24 billion, and management believes this will fund planned operations for at least twelve months from issuance. The company continues to invest heavily in its precision oncology pipeline, led by darovasertib in uveal melanoma with positive Phase 2/3 data and an NDA planned for the second half of 2026, alongside multiple ADC and synthetic lethality programs.
IDEAYA Biosciences reported second-quarter 2026 collaboration revenue of $8.9 million and a net loss of $112.5 million, driven mainly by $108.7 million in research and development spending and $22.5 million in general and administrative expenses. Cash, cash equivalents and marketable securities were approximately $1.24 billion as of June 30, 2026, and management reiterated cash runway guidance into 2030.
The registrational Phase 2/3 -02 darovasertib plus crizotinib trial in HLA*A2:01-negative metastatic uveal melanoma met its primary endpoint, showing median progression-free survival of 6.9 months versus 3.1 months for investigator’s choice by blinded independent central review. A new drug application is underway under the FDA’s real-time oncology review program, alongside broad pipeline progress in ADC, MTAP-pathway, and KAT6/7 programs and a recent $323.4 million equity financing.
Vanguard Capital Management filed a Schedule 13G reporting passive ownership of common stock of Ideaya Biosciences Inc. Vanguard and certain affiliated entities beneficially own 4,834,771 shares of Ideaya common stock, representing 5.08% of the class as of June 30, 2026.
Vanguard has sole voting power over 702,125 shares and sole dispositive power over all 4,834,771 shares, with no shared voting or dispositive power. The filing explains that this stake reflects securities held by Vanguard funds and managed accounts over which Vanguard and specified affiliates exercise voting and/or dispositive power, and notes that no other single person’s interest in these securities exceeds 5%.
IDEAYA Biosciences’ Chief Accounting Officer Andres Ruiz Briseno exercised stock options and sold shares in a pre-planned transaction. On July 7, 2026, he exercised 9,550 stock options at $12.86 per share to acquire common stock, then sold 9,550 common shares in open-market trades at a weighted average price of about $40.01 per share. The sale was executed under his Rule 10b5-1 trading plan adopted on December 19, 2025. Following these transactions, he directly owned 26,466 shares of IDEAYA Biosciences common stock.
IDEAYA Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026. As of the April 20, 2026 record date, 87,860,920 common shares were outstanding and entitled to vote.
Stockholders voted on three proposals. For director elections, Yujiro S. Hata received 70,546,418 votes for and 2,470,077 withheld, M. Garret Hampton received 56,718,637 for and 16,297,858 withheld, and Catherine J. Mackey received 70,281,521 for and 2,734,974 withheld, with 10,089,343 broker non-votes for each nominee.
PricewaterhouseCoopers LLP, as independent registered public accounting firm for the year ending December 31, 2026, received 82,579,758 votes for, 141,240 against, and 384,840 abstentions. The non-binding advisory vote on executive compensation received 64,269,756 votes for, 8,349,131 against, 397,608 abstentions, and 10,089,343 broker non-votes.
Effective June 16, 2026, the Board elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as Lead Independent Director.
IDEAYA Biosciences director Wendy L. Yarno received a grant of stock options for 20,000 shares of common stock at an exercise price of $30.57 per share. The options vest 100% on the earlier of one year from grant or immediately before the next Annual Meeting, subject to continued Board service, and expire on June 16, 2036.